The Latin America, Middle East and Africa Rapid Acting Insulin Market would witness market growth of 6.5% CAGR during the forecast period (2021-2027). By performing rapid-acting insulin opportunity analysis assessment, higher availability of constant glucose tracking will assist in complex analysis of clinic rapid insulin action which was not earlier feasible. This will assist in knowing whether the latest rapid-acting insulin opportunity analysis will offer a superior degree of optimal glycemic control above HbA1c levels, which is needed for regulatory and scientific compliance.
Rapid insulins can both be utilized for bolus doses of insulins. However, many individuals find that rapid-acting insulins are more convenient. Individuals suffering from either type 1 or type 2 diabetes can use rapid-acting insulins. These insulins show rapid action and hence can be taken before the meal. Similarly, it is easy to compare the increase in blood glucose from food absorption to gain the insulin in the blood from the rapid-acting insulin.
The increasing rate of diabetes around the world is expected to create growth avenues for the global rapid insulin market in the next few years. In addition to it, the growth of the market is further propelled by the growing number of research and development (R&D) activities for human recombinant insulin. Moreover, sedentary & unhealthy lifestyle patterns increase the risk of diabetes, as factors like overweight or obesity, an unhealthy diet & physical inactivity are responsible for the majority of diabetes diseases among people.
The Brazil market dominated the LAMEA Insulin Glulisine Market by Country in 2020, growing at a CAGR of 6.3 % during the forecast period. The Argentina market would witness a CAGR of 8% during (2021 - 2027). Additionally, The UAE market is experiencing a CAGR of 7.1% during (2021 - 2027).
The Drug Stores & Retail Pharmacies market dominated the South Africa Rapid Acting Insulin Market by Distribution Channel in 2020, thereby, achieving a market value of $69.2 Million by 2027. The Hospital Pharmacies market is estimated to grow at a CAGR of 7.6% during (2021 - 2027). The Online Providers market is expected to witness a CAGR of 8.1% during (2021 - 2027).
Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine. Based on Indication, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Rapid Acting Insulin Market is Predict to reach $11.4 Billion by 2027, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Adocia SA, Biocon Limited, Gan & Lee Pharmaceuticals, Geropharm LLC, Wockhardt Ltd., and MannKind Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Product Type
- Insulin Lispro
- Insulin Aspart
- Insulin Glulisine
By Indication
- Type 2 Diabetes
- Type 1 Diabetes
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Sanofi S.A.
- Novo Nordisk A/S
- Eli Lilly and Company
- Adocia SA
- Biocon Limited
- Gan & Lee Pharmaceuticals
- Geropharm LLC
- Wockhardt Ltd.
- MannKind Corporation
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Rapid Acting Insulin Market, by Product Type
1.4.2 LAMEA Rapid Acting Insulin Market, by Indication
1.4.3 LAMEA Rapid Acting Insulin Market, by Distribution Channel
1.4.4 LAMEA Rapid Acting Insulin Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
Chapter 4. LAMEA Rapid Acting Insulin Market by Product Type
4.1 LAMEA Insulin Lispro Market by Country
4.2 LAMEA Insulin Aspart Market by Country
4.3 LAMEA Insulin Glulisine Market by Country
Chapter 5. LAMEA Rapid Acting Insulin Market by Indication
5.1 LAMEA Type 2 Diabetes Market by Country
5.2 LAMEA Type 1 Diabetes Market by Country
Chapter 6. LAMEA Rapid Acting Insulin Market by Distribution Channel
6.1 LAMEA Hospital Pharmacies Market by Country
6.2 LAMEA Drug Stores & Retail Pharmacies Market by Country
6.3 LAMEA Online Providers Market by Country
Chapter 7. LAMEA Rapid Acting Insulin Market by Country
7.1 Brazil Rapid Acting Insulin Market
7.1.1 Brazil Rapid Acting Insulin Market by Product Type
7.1.2 Brazil Rapid Acting Insulin Market by Indication
7.1.3 Brazil Rapid Acting Insulin Market by Distribution Channel
7.2 Argentina Rapid Acting Insulin Market
7.2.1 Argentina Rapid Acting Insulin Market by Product Type
7.2.2 Argentina Rapid Acting Insulin Market by Indication
7.2.3 Argentina Rapid Acting Insulin Market by Distribution Channel
7.3 UAE Rapid Acting Insulin Market
7.3.1 UAE Rapid Acting Insulin Market by Product Type
7.3.2 UAE Rapid Acting Insulin Market by Indication
7.3.3 UAE Rapid Acting Insulin Market by Distribution Channel
7.4 Saudi Arabia Rapid Acting Insulin Market
7.4.1 Saudi Arabia Rapid Acting Insulin Market by Product Type
7.4.2 Saudi Arabia Rapid Acting Insulin Market by Indication
7.4.3 Saudi Arabia Rapid Acting Insulin Market by Distribution Channel
7.5 South Africa Rapid Acting Insulin Market
7.5.1 South Africa Rapid Acting Insulin Market by Product Type
7.5.2 South Africa Rapid Acting Insulin Market by Indication
7.5.3 South Africa Rapid Acting Insulin Market by Distribution Channel
7.6 Nigeria Rapid Acting Insulin Market
7.6.1 Nigeria Rapid Acting Insulin Market by Product Type
7.6.2 Nigeria Rapid Acting Insulin Market by Indication
7.6.3 Nigeria Rapid Acting Insulin Market by Distribution Channel
7.7 Rest of LAMEA Rapid Acting Insulin Market
7.7.1 Rest of LAMEA Rapid Acting Insulin Market by Product Type
7.7.2 Rest of LAMEA Rapid Acting Insulin Market by Indication
7.7.3 Rest of LAMEA Rapid Acting Insulin Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Merck & Co., Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.2 Sanofi S.A.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Product Launches and Product Expansions:
8.2.5.2 Approvals and Trials:
8.3 Novo Nordisk A/S
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental & Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.3.5.2 Approvals and Trials:
8.3.5.3 Partnerships, Collaborations, and Agreements:
8.4 Eli Lilly and Company
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.4.5.2 Approvals and Trials:
8.4.5.3 Partnerships, Collaborations, and Agreements:
8.5 Adocia SA
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Research & Development Expense
8.5.4 Recent strategies and developments:
8.5.4.1 Approvals and Trials:
8.6 Biocon Limited
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Approvals and Trials:
8.7 Gan & Lee Pharmaceuticals
8.7.1 Company Overview
8.7.2 Financial Analysis
8.8 Geropharm LLC
8.8.1 Company Overview
8.9 Wockhardt Ltd.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.10. MannKind Corporation
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expense
8.10.4 Recent strategies and developments:
8.10.4.1 Acquisition and Mergers:
8.10.4.2 Partnerships, Collaborations, and Agreements:
TABLE 1 LAMEA Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 2 LAMEA Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Rapid Acting Insulin Market]
TABLE 4 Product Launches And Product Expansions– Rapid Acting Insulin Market
TABLE 5 Acquisition and Mergers– Rapid Acting Insulin Market
TABLE 6 Approvals and Trials– Rapid Acting Insulin Market
TABLE 7 LAMEA Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 8 LAMEA Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 9 LAMEA Insulin Lispro Market by Country, 2017 - 2020, USD Million
TABLE 10 LAMEA Insulin Lispro Market by Country, 2021 - 2027, USD Million
TABLE 11 LAMEA Insulin Aspart Market by Country, 2017 - 2020, USD Million
TABLE 12 LAMEA Insulin Aspart Market by Country, 2021 - 2027, USD Million
TABLE 13 LAMEA Insulin Glulisine Market by Country, 2017 - 2020, USD Million
TABLE 14 LAMEA Insulin Glulisine Market by Country, 2021 - 2027, USD Million
TABLE 15 LAMEA Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 16 LAMEA Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 17 LAMEA Type 2 Diabetes Market by Country, 2017 - 2020, USD Million
TABLE 18 LAMEA Type 2 Diabetes Market by Country, 2021 - 2027, USD Million
TABLE 19 LAMEA Type 1 Diabetes Market by Country, 2017 - 2020, USD Million
TABLE 20 LAMEA Type 1 Diabetes Market by Country, 2021 - 2027, USD Million
TABLE 21 LAMEA Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 22 LAMEA Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 23 LAMEA Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 24 LAMEA Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 25 LAMEA Drug Stores & Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 26 LAMEA Drug Stores & Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 27 LAMEA Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 28 LAMEA Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 29 LAMEA Rapid Acting Insulin Market by Country, 2017 - 2020, USD Million
TABLE 30 LAMEA Rapid Acting Insulin Market by Country, 2021 - 2027, USD Million
TABLE 31 Brazil Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 32 Brazil Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 33 Brazil Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 34 Brazil Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 35 Brazil Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 36 Brazil Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 37 Brazil Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 38 Brazil Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 39 Argentina Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 40 Argentina Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 41 Argentina Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 42 Argentina Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 43 Argentina Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 44 Argentina Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 45 Argentina Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 46 Argentina Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 47 UAE Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 48 UAE Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 49 UAE Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 50 UAE Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 51 UAE Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 52 UAE Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 53 UAE Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 54 UAE Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 55 Saudi Arabia Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 56 Saudi Arabia Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 57 Saudi Arabia Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 58 Saudi Arabia Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 59 Saudi Arabia Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 60 Saudi Arabia Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 61 Saudi Arabia Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 62 Saudi Arabia Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 63 South Africa Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 64 South Africa Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 65 South Africa Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 66 South Africa Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 67 South Africa Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 68 South Africa Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 69 South Africa Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 70 South Africa Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 71 Nigeria Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 72 Nigeria Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 73 Nigeria Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 74 Nigeria Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 75 Nigeria Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 76 Nigeria Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 77 Nigeria Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 78 Nigeria Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 79 Rest of LAMEA Rapid Acting Insulin Market, 2017 - 2020, USD Million
TABLE 80 Rest of LAMEA Rapid Acting Insulin Market, 2021 - 2027, USD Million
TABLE 81 Rest of LAMEA Rapid Acting Insulin Market by Product Type, 2017 - 2020, USD Million
TABLE 82 Rest of LAMEA Rapid Acting Insulin Market by Product Type, 2021 - 2027, USD Million
TABLE 83 Rest of LAMEA Rapid Acting Insulin Market by Indication, 2017 - 2020, USD Million
TABLE 84 Rest of LAMEA Rapid Acting Insulin Market by Indication, 2021 - 2027, USD Million
TABLE 85 Rest of LAMEA Rapid Acting Insulin Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 86 Rest of LAMEA Rapid Acting Insulin Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 87 key information - Merck & Co., Inc.
TABLE 88 Key Information – Sanofi S.A.
TABLE 89 Key information – Novo Nordisk A/S
TABLE 90 Key Information – Eli Lilly and Company
TABLE 91 key information – Adocia SA
TABLE 92 Key Information – Biocon Limited
TABLE 93 Key Information – Gan & Lee Pharmaceuticals
TABLE 94 key Information – Geropharm LLC
TABLE 95 Key Information – Wockhardt Ltd.
TABLE 96 Key Information – MannKind Corporation
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2016-2020)
FIG 4 Recent strategies and developments: Novo Nordisk A/S
FIG 5 Recent strategies and developments: Eli Lilly and Company
FIG 6 Recent strategies and developments: MannKind Corporation